论文信息 - A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer - 字舞流文

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

T. Greten | G. Wilding | J. Kolesar | A. Doyle | D. Deming | A. Duffy | S. Lubner | Glenn Liu | D. Mulkerin | K. Compton | S. Fioravanti | N. Loconte | Ludmila L. Cavalcante | Sam J. Lubner | Daniel L. Mulkerin | Noelle K. LoConte | Jens C. Eickhoff | Tim F. Greten